Sarepta Therapeutics (SRPT) Could Be 28% Below Fair Value As New CEO Takes Over
Tracking Specialized Equities: Fox's Roku Buyout and Key C-Suite Reshuffles Drive Idiosyncratic Flow
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Receives Consensus Rating of "Hold" from Brokerages
Sarepta files Form 3 for CEO, director Michael Severino
Sarepta grants new CEO Severino options for 2,224,342 shares at $17.74, plus 756,104 RSUs
The Quiet AI Takeover of the Mundane Economy